Stack · Recovery
BPC-157 + TB-500
Discussed as a pairing of two compounds with connective-tissue research histories — BPC-157 for tendon, ligament, gut and muscle models; TB-500 as a fragment of thymosin β4, whose full-length parent has wound-healing literature. The pairing rationale is that the mechanisms are complementary; the sources that say this are overwhelmingly community and vendor material, not trials.
Compounds
Why people combine them
Discussed as a pairing of two compounds with connective-tissue research histories — BPC-157 for tendon, ligament, gut and muscle models; TB-500 as a fragment of thymosin β4, whose full-length parent has wound-healing literature. The pairing rationale is that the mechanisms are complementary; the sources that say this are overwhelmingly community and vendor material, not trials.
Evidence for the combination
No direct combination study is currently indexed by Therapept. What exists is evidence for each component separately — which is not evidence that combining them adds anything.
Evidence for each component
- BPC-157 — Animal evidence across tendon/gut models, largely from one research network; one small retrospective human case series; no registered human trials indexed.
- TB-500 — Wound-healing literature concerns full-length thymosin β4, a different molecule from the LKKTETQ fragment sold as TB-500; no human interventional evidence for the fragment is indexed.
Commonly reported dosing and protocols
Displayed source by source. Therapept does not compose these into a recommended protocol.
- COMMUNITYReddit r/Peptides (recurring posts)
Posts commonly describe ~200–500 mcg/day BPC-157 with ~2.0–2.5 mg TB-500 twice weekly, often in a shared syringe or same-site injections.
Reported practice, not a protocol from any clinical source. The TB-500 range traces to full-length Tβ4 animal work in most cases.
Checked 17 September 2026 · Community sources — see the dosing reference for limitations
- CLINICALClinic-published material (intra-articular series)
The Lee–Padgett series is the closest published human pairing: 4 of 16 patients received intra-articular BPC-157 with thymosin β-4 (named TB4 in the paper, which is not the TB-500 fragment) for knee complaints. Quantities are not stated in the abstract.
A retrospective chart review, not a trial; subsequent sports-medicine reviews treat it as methodologically inadequate for inference.
Checked 17 September 2026 · Lee and Padgett, Altern Ther Health Med (2021) — PubMed 34324435
Potential overlap and concerns
- Neither compound has an FDA-approved product; both appear on FDA's withdrawn-nominations compounding table with published immunogenicity and characterisation concerns.
- Both are prohibited in sport under the WADA 2026 Prohibited List (BPC-157 in S0; TB-500 at S2.3).
- The two substances most often discussed together are chemically distinct from what much of the cited literature studied (BPC-157's corpus is network-generated; TB-500's literature is mostly about full-length Tβ4).
What is known
- Each compound has a separate, largely preclinical evidence file.
- One small retrospective human series co-administered BPC-157 with thymosin β-4 (the parent molecule) intra-articularly.
What is speculative
- Any claim that the combination works better than either alone — no indexed study compares them jointly against either alone.
- Every community protocol ratio and frequency.
Sources
Last reviewed 17 September 2026 · Compiled by Therapept Editorial · How these records are built